Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TECZEM vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enalapril inhibits angiotensin-converting enzyme (ACE), reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Diltiazem inhibits calcium ion influx across cardiac and smooth muscle cells, causing coronary vasodilation and decreased myocardial contractility.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension,Stable angina,Chronic stable angina
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
1 to 2 tablets (enalapril 5 mg/diltiazem 180 mg) orally once daily. Maximum: 2 tablets daily.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Terminal elimination half-life: 3-4 hours for diltiazem; clinical context: requires twice-daily dosing due to short half-life.
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Enalapril is hydrolyzed to active enalaprilat, mainly hepatically. Diltiazem is extensively metabolized in the liver via CYP3A4.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Renal: 40-50% unchanged; hepatic/biliary/fecal: 50-60% as metabolites.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
70-80% bound to albumin and alpha-1-acid glycoprotein.
~20% bound to albumin; minimal binding to other plasma proteins.
5-7 L/kg; indicates extensive tissue distribution.
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: 35-60% due to first-pass metabolism; IV: 100%.
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
GFR >30 m L/min: No adjustment. GFR 10-30 m L/min: Use with caution, monitor potassium and creatinine. GFR <10 m L/min: Avoid use.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh A: No adjustment. Child-Pugh B: Use with caution, consider starting at lowest dose. Child-Pugh C: Contraindicated.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Safety and efficacy not established for patients <18 years.
Not recommended; inadequate safety data.
Start at lowest dose, monitor renal function and electrolytes due to age-related decreased renal function and increased sensitivity.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
Use in pregnancy: ACE inhibitors can cause injury and death to the developing fetus. Discontinue as soon as possible when pregnancy is detected.
None
Hypotension,Angioedema,Hepatic injury,Heart block,Bradycardia,Renal impairment,Hyperkalemia
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Hypersensitivity to enalapril, diltiazem, or any component,History of angioedema related to ACE inhibitors,Second- or third-degree AV block (except with pacemaker),Sick sinus syndrome,Severe hypotension,Cardiogenic shock,Concurrent use with riociguat
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid high-potassium foods (e.g., bananas, oranges, spinach) due to potential for hyperkalemia from enalapril. Grapefruit juice may increase diltiazem levels and should be limited or avoided. Alcohol can exacerbate hypotension.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
TECZEM (enalapril maleate and felodipine) is contraindicated in pregnancy. ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. First trimester exposure may be associated with a small increased risk of congenital anomalies; second and third trimester exposure is associated with oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal hypotension, anuria, and renal failure. Felodipine: No teratogenic effects in animal studies at clinically relevant doses; however, limited human data. Combined use should be avoided in pregnancy.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Enalapril is excreted in human milk in trace amounts; the M/P ratio is approximately 0.01. Felodipine is excreted in human milk; the M/P ratio is unknown. Due to potential for adverse effects in the nursing infant, especially renal effects from enalapril, breastfeeding is not recommended during TECZEM therapy.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
TECZEM is contraindicated in pregnancy. If a woman becomes pregnant while on TECZEM, discontinue the drug immediately. No dose adjustments are recommended as the drug should not be used. Alternative antihypertensive therapy should be considered if needed.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
TECZEM (enalapril/diltiazem ER) combines an ACE inhibitor and a non-dihydropyridine calcium channel blocker. Monitor renal function and serum potassium; avoid in patients with pre-existing high-grade AV block or severe left ventricular dysfunction. Use with caution in patients with hepatic impairment due to diltiazem metabolism. May cause reflex tachycardia less frequently than dihydropyridines.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take this medication exactly as prescribed; do not crush or chew the extended-release tablet.,Monitor blood pressure regularly and report symptoms such as dizziness, fainting, or irregular heartbeat.,Avoid salt substitutes containing potassium unless directed by your doctor.,Report any signs of angioedema (swelling of face, lips, tongue, or difficulty breathing) immediately.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TECZEM vs ALDORIL D50, answered by our medical review team.
TECZEM is a Antihypertensive combination that works by Enalapril inhibits angiotensin-converting enzyme (ACE), reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Diltiazem inhibits calcium ion influx across cardiac and smooth muscle cells, causing coronary vasodilation and decreased myocardial contractility.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TECZEM and ALDORIL D50 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TECZEM is: 1 to 2 tablets (enalapril 5 mg/diltiazem 180 mg) orally once daily. Maximum: 2 tablets daily.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TECZEM and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TECZEM is classified as Category C. TECZEM (enalapril maleate and felodipine) is contraindicated in pregnancy. ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. Firs. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.